Dec 21, 2016
Downward pricing pressures, restrictions on sales representation within hospitals and a push towards value based healthcare fostered ongoing uncertainty in the Medical Device Industry in 2016. Companies responded by consolidating, leveraging commercial infrastructures...
Dec 14, 2016
Last week, both chambers of Congress voted nearly unanimously to pass the 21st Century Cures Act (the Cures Act), sweeping legislation that directly impacts the government funding and FDA review process of medical innovations, both pharmaceutical and device. ...
Dec 7, 2016
This week Locust Walk announced the opening of our first office in Europe, which will initially be in Germany. Since this is a big step for our firm and builds on our success in Japan, we wanted to share the rationale for why we thought going into Europe made sense....
Dec 1, 2016
The recent flurry of partnering deals for Immuno-Oncology (IO) technologies surpasses the deal activity for any other technology at any other time in biotech history. In the past two years, there have been 31 development stage IO deals with up-front values greater...
Nov 22, 2016
The classic adage teaches that it is better to have a certain, but perhaps lesser than expected, outcome than the possibility of something greater that may never come. This lesson holds true for dealing with biopharma transactions. The difficulty of managing an offer...
